Selectively Hampered Activation of Lymph Node-resident Dendritic Cells Precedes Profound T Cell Suppression and Metastatic Spread in the Breast Cancer Sentinel Lymph Node

Overview

Journal J Immunother Cancer

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 2019 May 24

PMID 31118093

Citations 38

Authors

Kim M van Pul

Ronald J C L M Vuylsteke

Rieneke van de Ven

Elisabeth A Te Velde

Emiel J Th Rutgers

Petrousjka M van den Tol

Hein B A C Stockmann

Tanja D de Gruijl

Affiliations

Soon will be listed here.

Abstract

Background: Immune regulated pathways influence both breast cancer (BrC) development and response to (neo)adjuvant chemotherapy. The sentinel lymph node (SLN), as the first metastatic site, is also the first site where BrC-induced suppression of immune effector subsets occurs. Since intricate knowledge of the phenotypic and functional status of these immune effector subsets is lacking, we set out to map the immune landscape of BrC SLN.

Methods: Viable LN cells from BrC SLN (n = 58) were used for detailed flowcytometry-assisted mapping of the immune landscape of BrC SLN in a comparative analysis with healthy (i.e. prophylactic mastectomy-derived) axillary lymph nodes (HLN, n = 17). Findings were related to clinicopathological characteristics.

Results: Our data show that BrC-induced immune suppression in tumor-involved SLN, as evidenced by increased Treg and MDSC rates as well as by a generalized state of T cell anergy, coincides with hampered activation of LN-resident (LNR) dendritic cell (DC) subsets rather than of migratory DC subsets. Importantly, suppression of these LN-resident DC subsets preceded profoundly disabled T cell effector functions in tumor-involved SLN. Furthermore, we provide evidence that the suppressed state of LNR-cDC is not only related to nodal involvement but is also related to high-risk breast cancer subtypes that lack expression of hormone receptors and may be a negative predictor of disease-free survival.

Conclusion: These data thus provide new insights in the mechanisms underlying loco-regional immune suppression induced by BrC and how these relate to clinical outcome. They identify the LNR-cDC subset as a pivotal regulatory node in cellular immune suppressive pathways and therefore as a promising therapeutic target to combat immune suppression and secure the induction of effective antitumor immunity, e.g. in combination with neo-adjuvant chemotherapy. .

Citing Articles

Guidelines for preparation and flow cytometry analysis of human nonlymphoid tissue DC.

Dudziak D, Heger L, Agace W, Bakker J, de Gruijl T, Dress R Eur J Immunol. 2024; 55(1):e2250325.

PMID: 39668411 PMC: 11739683. DOI: 10.1002/eji.202250325.

Therapeutic Immunomodulation of Tumor-Lymphatic Crosstalk via Intratumoral Immunotherapy.

Lucas S, Thomas S Mol Pharm. 2024; 21(12):5929-5943.

PMID: 39478434 PMC: 11615947. DOI: 10.1021/acs.molpharmaceut.4c00692.

Difference between sentinel and non-sentinel lymph nodes in the distribution of dendritic cells and macrophages: An immunohistochemical and morphometric study using gastric regional nodes obtained in sentinel node navigation surgery for early....

Sonoda T, Arigami T, Aoki M, Matsushita D, Shimonosono M, Tsuruda Y J Anat. 2024; 246(2):272-287.

PMID: 39367691 PMC: 11737316. DOI: 10.1111/joa.14147.

CD4 T cells in antitumor immunity.

Montauti E, Oh D, Fong L Trends Cancer. 2024; 10(10):969-985.

PMID: 39242276 PMC: 11464182. DOI: 10.1016/j.trecan.2024.07.009.

SPP1 TAM Regulates the Metastatic Colonization of CXCR4 Metastasis-Associated Tumor Cells by Remodeling the Lymph Node Microenvironment.

Dong L, Hu S, Li X, Pei S, Jin L, Zhang L Adv Sci (Weinh). 2024; 11(44):e2400524.

PMID: 39236316 PMC: 11600252. DOI: 10.1002/advs.202400524.

References

van den Hout M, Koster B, Sluijter B, Molenkamp B, van de Ven R, van den Eertwegh A . Melanoma Sequentially Suppresses Different DC Subsets in the Sentinel Lymph Node, Affecting Disease Spread and Recurrence. Cancer Immunol Res. 2017; 5(11):969-977. DOI: 10.1158/2326-6066.CIR-17-0110. View

Matsuura K, Yamaguchi Y, Ueno H, Osaki A, Arihiro K, Toge T . Maturation of dendritic cells and T-cell responses in sentinel lymph nodes from patients with breast carcinoma. Cancer. 2006; 106(6):1227-36. DOI: 10.1002/cncr.21729. View

Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D . Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014; 25(8):1544-50. DOI: 10.1093/annonc/mdu112. View

Schreibelt G, Tel J, Sliepen K, Benitez-Ribas D, Figdor C, Adema G . Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother. 2010; 59(10):1573-82. PMC: 11029854. DOI: 10.1007/s00262-010-0833-1. View

Jongbloed S, Kassianos A, McDonald K, Clark G, Ju X, Angel C . Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med. 2010; 207(6):1247-60. PMC: 2882828. DOI: 10.1084/jem.20092140. View

DeNardo D, Brennan D, Rexhepaj E, Ruffell B, Shiao S, Madden S . Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011; 1(1):54-67. PMC: 3203524. DOI: 10.1158/2159-8274.CD-10-0028. View

Torrenga H, Meijer S, Fabry H, van der Sijp J . Sentinel node biopsy in breast cancer patients: triple technique as a routine procedure. Ann Surg Oncol. 2004; 11(3 Suppl):231S-5S. DOI: 10.1007/BF02523635. View

Koster B, van den Hout M, Sluijter B, Molenkamp B, Vuylsteke R, Baars A . Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage I-II Melanoma: Data from Two Randomized Phase II Trials. Clin Cancer Res. 2017; 23(19):5679-5686. DOI: 10.1158/1078-0432.CCR-17-0944. View

Duraiswamy J, Kaluza K, Freeman G, Coukos G . Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 2013; 73(12):3591-603. PMC: 3686913. DOI: 10.1158/0008-5472.CAN-12-4100. View

10.

Andre F, Dieci M, Dubsky P, Sotiriou C, Curigliano G, Denkert C . Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. Clin Cancer Res. 2012; 19(1):28-33. DOI: 10.1158/1078-0432.CCR-11-2701. View

11.

Hu X, Stern H, Ge L, OBrien C, Haydu L, Honchell C . Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol Cancer Res. 2009; 7(4):511-22. DOI: 10.1158/1541-7786.MCR-08-0107. View

12.

Ghirelli C, Reyal F, Jeanmougin M, Zollinger R, Sirven P, Michea P . Breast Cancer Cell-Derived GM-CSF Licenses Regulatory Th2 Induction by Plasmacytoid Predendritic Cells in Aggressive Disease Subtypes. Cancer Res. 2015; 75(14):2775-87. DOI: 10.1158/0008-5472.CAN-14-2386. View

13.

Segura E, Valladeau-Guilemond J, Donnadieu M, Sastre-Garau X, Soumelis V, Amigorena S . Characterization of resident and migratory dendritic cells in human lymph nodes. J Exp Med. 2012; 209(4):653-60. PMC: 3328358. DOI: 10.1084/jem.20111457. View

14.

Elliott B, Cook M, John R, Powell B, Pandha H, Dalgleish A . Successful live cell harvest from bisected sentinel lymph nodes research report. J Immunol Methods. 2004; 291(1-2):71-8. DOI: 10.1016/j.jim.2004.04.025. View

15.

Heath W, Belz G, Behrens G, Smith C, Forehan S, Parish I . Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev. 2004; 199:9-26. DOI: 10.1111/j.0105-2896.2004.00142.x. View

16.

Bergenfelz C, Larsson A, von Stedingk K, Gruvberger-Saal S, Aaltonen K, Jansson S . Systemic Monocytic-MDSCs Are Generated from Monocytes and Correlate with Disease Progression in Breast Cancer Patients. PLoS One. 2015; 10(5):e0127028. PMC: 4439153. DOI: 10.1371/journal.pone.0127028. View

17.

Metzger-Filho O, Sun Z, Viale G, Price K, Crivellari D, Snyder R . Patterns of Recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX. J Clin Oncol. 2013; 31(25):3083-90. PMC: 3753700. DOI: 10.1200/JCO.2012.46.1574. View

18.

Bembenek A, Li J, Loddenkemper C, Kemmner W, STEIN H, Wernecke K . Presence of mature DC-Lamp+ dendritic cells in sentinel and non-sentinel lymph nodes of breast cancer patients. Eur J Surg Oncol. 2007; 34(5):514-8. DOI: 10.1016/j.ejso.2007.05.013. View

19.

. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365(9472):1687-717. DOI: 10.1016/S0140-6736(05)66544-0. View

20.

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View